Shruthi Donthi

Shruthi Donthi supports clients with data-driven analyses that leverage medical claims and other healthcare data to understand policy impacts on business decisions and strategies for a wide variety of stakeholders.

Prior to joining Avalere, Shruthi was a research analyst fellow with the FDA analyzing drug product and manufacturer data, creating reports, and performing data validation to improve the efficiency and quality of the Office of Surveillance’s Product and Site Catalog. Prior to that role, she was a SAS programmer conducting analyses to facilitate drug inspection and surveillance efforts. Additionally, Shruthi has graduate research experience analyzing Medicare claims and electronic health record data.

Shruthi has an MS in management information systems, data analytics from Oklahoma State University, an MBA in finance, and a BTech in electronics and communications engineering from Jawaharlal Nehru Technological University in India.

Authored Content

New analysis from Avalere finds 52% of Part D plans achieve generic substitution1 rates above 75%.

Avalere analysis finds that payment to Medicare Advantage (MA) plans for end-stage renal disease (ESRD) patients in highly populated regions may be significantly below actual patient costs.

Medicare Advantage (MA) plans continue expanding coverage of supplemental benefits following administration’s policy changes from a year ago.

As policymakers consider reforms to the Part D benefit to address rising out-of-pocket (OOP) costs by adding a maximum OOP cap, an Avalere analysis examines the types of beneficiaries mostly likely to be helped by such a policy.

Avalere analysis finds that tying Medicare Part D manufacturer discounts to utilization in the catastrophic phase instead of in the coverage gap would have differential impacts by disease area.

In a new analysis, Avalere examines the implications of CMS’ potential new requirement that Part D plans place generics only on generic tiers.